FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Phase 2 Completed 194 enrolled Genentech, Inc. SCRI Development Innovations, LLC · collab

Parallel-groupDouble-blindTreatment

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of FOLFOX/bevacizumab with onartuzumab (MetMAb) versus placebo as first-line treatment in patients with metastatic colorectal cancer.

Timeline

Start: 2011-09-14
Primary completion: 2013-03-18
Completion: 2013-03-18

Publications

Bendell JC, Hochster H, Hart LL, Firdaus I, Mace JR, McFarlane JJ, Kozloff M, Catenacci D, Hsu JJ, Hack SP, Shames DS, Phan SC, Koeppen H, Cohn AL. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer. Oncologist. 2017 Mar;22(3):264-271. doi: 10.1634/theoncologist.2016-0223. Epub 2017 Feb 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Onartuzumab	Monoclonal antibody	10 mg/kg	Intravenous
Background	Bevacizumab	Monoclonal antibody	5 mg/kg	Intravenous
Background	Leucovorin	Small molecule	—	Intravenous
Background	fluorouracil	Small molecule	—	Intravenous

FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Summary

Timeline

Publications

Drugs

Indications